Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalKorean Journal of Internal Medicine
Volume26
Issue number2
DOIs
StatePublished - 1 Jun 2011

Fingerprint

Multidrug-Resistant Tuberculosis
Levofloxacin
Extensively Drug-Resistant Tuberculosis
Therapeutics
Ofloxacin
moxifloxacin
Pharmaceutical Preparations
Odds Ratio
Demography
Confidence Intervals
Incidence

Keywords

  • Levofloxacin
  • Moxifloxacin
  • Multidrug-resistant
  • Quinolones
  • Tuberculosis

Cite this

@article{8b8e179d65334d1e9ed8e124ca28713a,
title = "Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes",
abstract = "Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56{\%} of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9{\%}) received levofloxacin for a median 594 days, and 48 patients (28.1{\%}) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9{\%} in the levofloxacin group and 83.3{\%} in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95{\%} confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.",
keywords = "Levofloxacin, Moxifloxacin, Multidrug-resistant, Quinolones, Tuberculosis",
author = "Jinwoo Lee and Lee, {Chang Hoon} and Kim, {Deog Kyeom} and Yoon, {Ho Il} and Kim, {Jae Yeol} and Lee, {Sang Min} and Yang, {Seok Chul} and Lee, {Jae Ho} and Yoo, {Chul Gyu} and Lee, {Choon Taek} and Chung, {Hee Soon} and Kim, {Young Whan} and Han, {Sung Koo} and Yim, {Jae Joon}",
year = "2011",
month = "6",
day = "1",
doi = "10.3904/kjim.2011.26.2.153",
language = "English",
volume = "26",
pages = "153--159",
journal = "The Korean journal of internal medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes

AU - Lee, Jinwoo

AU - Lee, Chang Hoon

AU - Kim, Deog Kyeom

AU - Yoon, Ho Il

AU - Kim, Jae Yeol

AU - Lee, Sang Min

AU - Yang, Seok Chul

AU - Lee, Jae Ho

AU - Yoo, Chul Gyu

AU - Lee, Choon Taek

AU - Chung, Hee Soon

AU - Kim, Young Whan

AU - Han, Sung Koo

AU - Yim, Jae Joon

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.

AB - Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.

KW - Levofloxacin

KW - Moxifloxacin

KW - Multidrug-resistant

KW - Quinolones

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=79959818137&partnerID=8YFLogxK

U2 - 10.3904/kjim.2011.26.2.153

DO - 10.3904/kjim.2011.26.2.153

M3 - Article

C2 - 21716591

AN - SCOPUS:79959818137

VL - 26

SP - 153

EP - 159

JO - The Korean journal of internal medicine

JF - The Korean journal of internal medicine

SN - 1226-3303

IS - 2

ER -